0001179110-20-002963.txt : 20200303 0001179110-20-002963.hdr.sgml : 20200303 20200303191100 ACCESSION NUMBER: 0001179110-20-002963 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200301 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Albers Jeffrey W. CENTRAL INDEX KEY: 0001638474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 20684938 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-03-01 0 0001597264 Blueprint Medicines Corp BPMC 0001638474 Albers Jeffrey W. C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2020-03-01 4 A 0 45000 0 A 123711 D Stock Option (Right to Buy) 54.13 2020-03-01 4 A 0 90000 0 A 2030-03-01 Common Stock 90000 90000 D The reported transaction involved the Reporting Person's receipt of a grant of 45,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 45,000 newly awarded restricted stock units, 29,750 previously reported restricted stock units, 7,438 of which vested on March 1, 2020, and 48,961 shares of common stock. This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-03-03